<DOC>
	<DOCNO>NCT00473590</DOCNO>
	<brief_summary>This randomize , blind , placebo-controlled , multicenter , Phase II study design provide preliminary assessment safety efficacy combine bevacizumab bortezomib patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With Bortezomib Patients With Relapsed Refractory Multiple Myeloma ( AMBER )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Previously diagnose multiple myeloma Relapsed refractory multiple myeloma disease progression follow one three prior treatment regimen Measurable multiple myeloma disease Grade ≥ 2 peripheral neuropathy Use corticosteroid within 21 day prior Day 1 Use antimyeloma therapy within 21 day prior Day 1 Intolerance bortezomib compound contain boron Life expectancy &lt; 12 week Current , recent , planned participation experimental drug study Active malignancy multiple myeloma within 5 year screen Prior treatment bevacizumab Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great congestive heart failure ( CHF ) Decreased left ventricular function study entry History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Significant vascular disease recent peripheral arterial thrombosis within 6 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study Core biopsy minor surgical procedure , include placement vascular access device within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture ( pathologic bone fracture consistent multiple myeloma , patient may eligible treatment plan ) Albuminuria Known hypersensitivity component bevacizumab Pregnancy ( positive pregnancy test ) lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Avastin</keyword>
	<keyword>AMBER</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Velcade</keyword>
</DOC>